Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection.

Chen, Wujun; Shao, Yingchun; Peng, Xiaojin; Liang, Bing; Xu, Jiazhen; Xing, Dongming

Chen, Wujun; Shao, Yingchun; Peng, Xiaojin; Liang, Bing; Xu, Jiazhen; Xing, Dongming.

Afiliação

Chen W; Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Shao Y; Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Peng X; Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Liang B; Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Xu J; Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Xing D; Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, China.

Front Pharmacol ; 13: 1035969, 2022.

Article em En | MEDLINE | ID: mdl-36438815

Palavras-chave

PF-07304814; SARS-CoV-2; derivatives; pharmacokinetics; pharmacology; toxicology

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google